Hope for the elderly: First participants receive VPM1002 in a late-stage phase III clinical trial in Germany
Vakzine Projekt Management GmbH (VPM) announces that the first participants have been enrolled last week in the phase III trial to test the efficacy of the vaccine candidate VPM1002 in preventing COVID-19 and other respiratory diseases. The large-scale, multicentre clinical trial has started in Berlin and will soon be rolled out to other sites in Germany. The clinical trial will include elderly participants. More!